2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts-PP01.059 Mary Gwin NACLC23 Abstract

PP01.059 Mary Gwin NACLC23 Abstract

Pdf Summary

A study conducted at Parkland Health in Dallas, Texas, evaluated mortality in a large and diverse lung cancer screening (LCS) cohort. The study aimed to determine overall survival rates among patients undergoing LCS in the real world, as previous LCS trial populations may not accurately represent the broader population. The study included 1,599 patients with a mean age of 62.5 years, 43% female, 45% Black, and 18% Hispanic. 70% had moderate comorbidity, and 9% had severe comorbidity.<br /><br />The findings of the study indicated that short-term mortality in the LCS population was minimal. With a median follow-up of 17 months, only 2% of patients had died. For patients without a date of death, 75% had an encounter in the healthcare system within three months of data collection. The study did not find any significant associations between survival rates and sex, race, comorbidity, smoking status, or LCS completion. However, there was a near-significant association with age.<br /><br />The results suggest that despite the significant comorbidity burden among patients undergoing LCS, short-term mortality rates are low. The study highlights the importance of longer follow-up in assessing the benefits of LCS, particularly among older individuals. Further research on contemporary LCS cohorts will help identify which patients are less likely to benefit from LCS.<br /><br />Overall, this study provides valuable insights into the real-world mortality rates among a diverse LCS population. The findings suggest that LCS can potentially be beneficial in reducing mortality from lung cancer in this cohort. Further research with longer follow-up is needed to better understand the impact of LCS and identify individuals who may benefit the most from this screening approach.

Keywords

Parkland Health

Dallas

mortality

lung cancer screening

real world

overall survival rates

LCS cohort

comorbidity

short-term mortality

follow-up